Nivolumab (Opdivo°) and metastatic or inoperable lung cancer

Prescrire Int. 2017 Apr;26(181):93-94.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Docetaxel / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Neoplasm Metastasis
  • Nivolumab / therapeutic use*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Docetaxel
  • Nivolumab